QQQ   440.84 (-0.72%)
AAPL   171.05 (-2.31%)
MSFT   412.46 (-0.59%)
META   493.67 (-0.91%)
GOOGL   131.90 (-1.09%)
AMZN   176.30 (-0.72%)
TSLA   182.51 (-2.99%)
NVDA   858.32 (+0.70%)
NIO   5.20 (-2.44%)
AMD   200.79 (-2.23%)
BABA   71.30 (-0.97%)
T   16.97 (+1.01%)
F   12.70 (-0.31%)
MU   94.08 (-1.76%)
CGC   2.98 (-1.32%)
GE   160.56 (-0.28%)
DIS   113.29 (-0.35%)
AMC   4.24 (-1.85%)
PFE   25.95 (+0.23%)
PYPL   59.32 (-1.10%)
XOM   103.99 (-0.35%)
QQQ   440.84 (-0.72%)
AAPL   171.05 (-2.31%)
MSFT   412.46 (-0.59%)
META   493.67 (-0.91%)
GOOGL   131.90 (-1.09%)
AMZN   176.30 (-0.72%)
TSLA   182.51 (-2.99%)
NVDA   858.32 (+0.70%)
NIO   5.20 (-2.44%)
AMD   200.79 (-2.23%)
BABA   71.30 (-0.97%)
T   16.97 (+1.01%)
F   12.70 (-0.31%)
MU   94.08 (-1.76%)
CGC   2.98 (-1.32%)
GE   160.56 (-0.28%)
DIS   113.29 (-0.35%)
AMC   4.24 (-1.85%)
PFE   25.95 (+0.23%)
PYPL   59.32 (-1.10%)
XOM   103.99 (-0.35%)
QQQ   440.84 (-0.72%)
AAPL   171.05 (-2.31%)
MSFT   412.46 (-0.59%)
META   493.67 (-0.91%)
GOOGL   131.90 (-1.09%)
AMZN   176.30 (-0.72%)
TSLA   182.51 (-2.99%)
NVDA   858.32 (+0.70%)
NIO   5.20 (-2.44%)
AMD   200.79 (-2.23%)
BABA   71.30 (-0.97%)
T   16.97 (+1.01%)
F   12.70 (-0.31%)
MU   94.08 (-1.76%)
CGC   2.98 (-1.32%)
GE   160.56 (-0.28%)
DIS   113.29 (-0.35%)
AMC   4.24 (-1.85%)
PFE   25.95 (+0.23%)
PYPL   59.32 (-1.10%)
XOM   103.99 (-0.35%)
QQQ   440.84 (-0.72%)
AAPL   171.05 (-2.31%)
MSFT   412.46 (-0.59%)
META   493.67 (-0.91%)
GOOGL   131.90 (-1.09%)
AMZN   176.30 (-0.72%)
TSLA   182.51 (-2.99%)
NVDA   858.32 (+0.70%)
NIO   5.20 (-2.44%)
AMD   200.79 (-2.23%)
BABA   71.30 (-0.97%)
T   16.97 (+1.01%)
F   12.70 (-0.31%)
MU   94.08 (-1.76%)
CGC   2.98 (-1.32%)
GE   160.56 (-0.28%)
DIS   113.29 (-0.35%)
AMC   4.24 (-1.85%)
PFE   25.95 (+0.23%)
PYPL   59.32 (-1.10%)
XOM   103.99 (-0.35%)
NASDAQ:HRMY

Harmony Biosciences (HRMY) Stock Price, News & Analysis

$31.00
+0.13 (+0.42%)
(As of 08:27 AM ET)
Today's Range
$31.00
$31.00
50-Day Range
$30.32
$35.06
52-Week Range
$18.61
$45.17
Volume
500 shs
Average Volume
337,911 shs
Market Capitalization
$1.76 billion
P/E Ratio
14.62
Dividend Yield
N/A
Price Target
$41.00

Harmony Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
32.8% Upside
$41.00 Price Target
Short Interest
Bearish
20.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.06mentions of Harmony Biosciences in the last 14 days
Based on 13 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
31.33%
From $3.00 to $3.94 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.45 out of 5 stars

Medical Sector

139th out of 960 stocks

Pharmaceutical Preparations Industry

56th out of 446 stocks


HRMY stock logo

About Harmony Biosciences Stock (NASDAQ:HRMY)

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

HRMY Stock Price History

HRMY Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Detecting Cancer in Mere Seconds: Early Investment Opportunity
A revolutionary cancer diagnostic tool is likely to come to fruition with anticipated FDA approval expected in just months. With the ability to detect cancer's "molecular fingerprint" in just seconds, it also offers far superior accuracy to current detection methods and reduces the need for invasive biopsies.
Harmony Biosciences Receives FDA Priority Review For Wakix
HRMY Mar 2024 30.000 call
Harmony Biosciences Holdings (HRMY)
HRMY vs. RGEN: Which Stock Is the Better Value Option?
See More Headlines
Receive HRMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/05/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:HRMY
Fax
N/A
Employees
200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$41.00
High Stock Price Target
$59.00
Low Stock Price Target
$27.00
Potential Upside/Downside
+32.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

Net Income
$128.85 million
Pretax Margin
29.79%

Debt

Sales & Book Value

Annual Sales
$582.02 million
Cash Flow
$2.51 per share
Book Value
$7.97 per share

Miscellaneous

Free Float
37,070,000
Market Cap
$1.75 billion
Optionable
Optionable
Beta
0.72
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Jeffrey S. Aronin (Age 56)
    Founder & Non-Executive Chairman
    Comp: $19.6k
  • Dr. Jeffrey M. Dayno M.D. (Age 67)
    President, CEO & Director
    Comp: $762.15k
  • Mr. Sandip S. Kapadia CPA (Age 54)
    M.B.A., Executive VP, Chief Administrative Officer & CFO
    Comp: $962.6k
  • Mr. Jeffrey Dierks M.B.A.Mr. Jeffrey Dierks M.B.A. (Age 52)
    Executive VP & Chief Commercial Officer
    Comp: $662.1k
  • Mr. Andrew Serafin J.D. (Age 49)
    M.B.A., Executive VP & Chief Strategy Officer
    Comp: $605.42k
  • Mr. David Bradshaw
    Head of Technical Operations
  • Luis Sanay
    Head of Investor Relations
  • Mr. Christian Ulrich
    General Counsel & Corporate Secretary
  • Ms. Tricia Glover
    Chief Compliance Officer
  • Ms. Audrey Murphy
    Head of Human Resources














HRMY Stock Analysis - Frequently Asked Questions

Should I buy or sell Harmony Biosciences stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harmony Biosciences in the last year. There are currently 2 sell ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HRMY shares.
View HRMY analyst ratings
or view top-rated stocks.

What is Harmony Biosciences' stock price target for 2024?

8 brokers have issued 12 month price targets for Harmony Biosciences' shares. Their HRMY share price targets range from $27.00 to $59.00. On average, they predict the company's stock price to reach $41.00 in the next year. This suggests a possible upside of 32.8% from the stock's current price.
View analysts price targets for HRMY
or view top-rated stocks among Wall Street analysts.

How have HRMY shares performed in 2024?

Harmony Biosciences' stock was trading at $32.30 on January 1st, 2024. Since then, HRMY shares have decreased by 4.4% and is now trading at $30.87.
View the best growth stocks for 2024 here
.

When is Harmony Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our HRMY earnings forecast
.

How were Harmony Biosciences' earnings last quarter?

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) announced its quarterly earnings data on Thursday, February, 22nd. The company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.74 by $0.29. The company earned $168.40 million during the quarter, compared to analyst estimates of $168.90 million. Harmony Biosciences had a trailing twelve-month return on equity of 27.49% and a net margin of 22.16%. Harmony Biosciences's revenue for the quarter was up 31.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.01 EPS.

What guidance has Harmony Biosciences issued on next quarter's earnings?

Harmony Biosciences issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $700.0 million-$720.0 million, compared to the consensus revenue estimate of $712.3 million.

What other stocks do shareholders of Harmony Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harmony Biosciences investors own include Advance Auto Parts (AAP), Advanced Micro Devices (AMD), Boeing (BA), Berry Global Group (BERY), Bunge Global (BG), Carrier Global (CARR), Commercial Metals (CMC), Canadian Solar (CSIQ), Deere & Company (DE) and Eastman Chemical (EMN).

When did Harmony Biosciences IPO?

(HRMY) raised $101 million in an initial public offering on Wednesday, August 19th 2020. The company issued 4,700,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler served as the underwriters for the IPO.

Who are Harmony Biosciences' major shareholders?

Harmony Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (6.27%), Pacer Advisors Inc. (2.09%), Dimensional Fund Advisors LP (1.26%), abrdn plc (0.91%), Federated Hermes Inc. (0.90%) and Massachusetts Financial Services Co. MA (0.87%). Insiders that own company stock include Andreas Wicki, Jack Nielsen, Jeffrey Dierks, Jeffrey M Dayno, Jeffrey M Dayno, John C Jacobs and John C Jacobs.
View institutional ownership trends
.

How do I buy shares of Harmony Biosciences?

Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HRMY) was last updated on 3/5/2024 by MarketBeat.com Staff